Innate immunity and pathology of the critical patient
PRINCIPAL INVESTIGATORS
- Oriol Roca Gas
- Joan Sabater Riera
CLINICAL RESEARCHERS
- Luisa Corral Ansa
- Francesc Esteve Urbano
- Maria Paz Fuset Cabanes
- Gabriel Jesus Moreno Gonzalez
- Ana Rosa Ochagavía Calvo
- Eva Oliver Juan
- Jose Luis Perez Fernandez
- Arnau Ulsamer Riera
POSTDOCTORAL RESEARCHERS
- Sara Olivera Ardid
PREDOCTORAL RESEARCHERS
- Victor Daniel Gumucio Sanguino
SCIENTIFIC SUPPORT
- Daniel Iglesias Serret
- Diana Kaptoul Pique
Translational Medicine
Infectious disease and transplantation
Scientific production
16
PAPERS
Average IF: 10,29
6
LED PAPERS
Average IF: 14,85
6 PUBLICATIONS IN FIRST DECILE
13 PUBLICATIONS IN FIRST QUARTILE
11 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Pérez Fernández,X;Ulsamer,A;Sabater Riera,J, Extracorporeal Blood Purification and Acute Kidney Injury in Cardiac Surgery-Reply., JAMA, 2025;333(8):723-723, doi:10.1001/jama.2024.26216
- Frat,J;Grieco,DL;De Jong,A;Gibbs,K;Carteaux,G;Roca,O;Lemiale,V et al, Noninvasive respiratory supports in ICU, Intensive Care Med, 2025;51(8):1476-1489, doi:10.1007/s00134-025-08036-3
- Sánchez Vera,I;Cosialls,AM;Maritorena Hualde,N;Schuler,MH;Lavilla,R;Pons,G;Jae,LT et al, Targeting prohibitins activates the ISR through DELE1-HRI by impairing protein import into the mitochondrial matrix., Cell Death Differ, 2025;doi:10.1038/s41418-025-01618-0
- Capoulade R, Croyal M, Senage T, Guimbretière G, Le May C, Rodrigues Oliveira A, Carpentier M, Piriou N, Fellah-Hebia I, Costa C, Vadori M, Galiñanes M, Manez R, Serfaty JM, Soulillou JP, Cozzi E, Padler-Karavani V, Roussel JC, Cariou B, Le Tourneau T. Polymorphic Size of Lipoprotein(a) and Structural Bioprosthetic Valve Degeneration. JACC Cardiovasc Imaging. 2025 Oct;18(10):1167-1169. doi: 10.1016/j.jcmg.2025.05.007
- Wendel Garcia,PD;Ceccato,A;Motos,A;Franch Llasat,D;Perez Moreno,MO;Domenech Spanedda,MF;Chamarro Marti,E et al, Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort study, J Infect, 2025;90(2):106411-106411, doi:10.1016/j.jinf.2025.10641
Research highlights
PROJECTS
1 Granted competitive project
3 Ongoing competitive projects
6 Started clinical trials
15 Ongoing clinical trials
INNOVATION
2 Patents
2 Licenses
1 spin-off
Selected projects
- 101045956. COVend: Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19. COMISSIÓ EUROPEA. Budget: 114.101,66€. 2021-2025. PI: RAFAEL MAÑEZ MENDILUCE.
- TMP-2204-2021-47. Potencial del FX06 para aliviar la gravedad de la enfermedad en pacientes con Síndrome de Dificultad Respiratoria Aguda (IXION 2.0). F4Pharma GmbH i.G.. Budget: 112.500€. 2022-2026. PI: RAFAEL MAÑEZ MENDILUCE.”
- Safety and efficacy of oXiris during cardiopulmonary bypass. A safety and plausibility study on the effect of an adsorption device on cardiac surgery-associated acute kidney injury. Vantive Health S.L.. Budget: 94.733,36€. 2025-2027. PI: JOSE LUIS PEREZ FERNANDEZ.
- BTI-203. Estudio de fase 2, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de la gelsolina de plasma humano recombinante adyuvante con atención estándar para ARDS de moderados a severos debido a neumonía u otras infecciones. BioAegis Therapeutics, Inc. (BTI). Budget: 69.800€. 2025- . PI: ORIOL ROCA GAS, JOAN SABATER RIERA, RAFAEL MAÑEZ MENDILUCE.
- GC45428. A phase II, randomized, double-blind, placebo-controlled study of the efficacy and safety of GDC-8264 in preventing cardiac surgery associated acute kidney injury and major adverse kidney events.. Genentech, Inc.. Budget: 53.160€. 2025- . PI: JOAN SABATER RIERA.